

January 31, 2012
Gothenburg, Sweden

Conference call Year-end report 2011

Invitation to attend Vitrolife's conference call regarding presentation of the Year-end report for 2011. The presentation will be held in English.

Time: Tuesday, February 7, 2012 at 10.00 a.m. CET.

Registration can preferably be done in advance under the following link:

<https://eventreg2.conferencing.com/webportal3/reg.html?Acc=526965&Conf=207356>

or shortly before time of the conference starts on:

Sweden dial in number: +46 (0)8 505 201 14

UK dial in number: +44 (0)20 7162 0177

Conference name: Vitrolife, conference ID: 911127

Vitrolife participants:

Thomas Axelsson, acting CEO

Mikael Engblom, CFO

The press release for Vitrolife's Year-end report will be released at 8.30 CET on the same day.

Before the conference call, slides will be available at the company web page,

www.vitrolife.com/sv/Corporate/.

A recorded version of the presentation will be available for seven days on number +46 8 505 203 33 (Sweden) or 020 7031 4064 (UK), access code 911127.

Gothenburg, January 31, 2012

VITROLIFE AB (publ)

Queries should be addressed to:

Mikael Engblom, CFO, phone +46 31 721 80 14

Vitrolife is a global biotechnology/medical device Group that has business activities within the areas of fertility and transplantation. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. There is also business to enable the use and handling of stem cells for therapeutic purposes. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body in order to select usable organs and keep them in optimal condition while waiting for transplantation.

Vitrolife today has approximately 220 employees and its products are sold in almost 90 markets. The company is headquartered in Gothenburg, Sweden, and there are offices in USA, Australia, France, Italy, United Kingdom, China and Japan. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.
Tel: 46 31 721 80 00. Fax: 46 31 721 80 90. E-mail: info@vitrolife.com. Website: www.vitrolife.com